Pediatric Tuberculous Meningitis: Model-Based Approach to Determining Optimal Doses of the Anti-Tuberculosis Drugs Rifampin and Levofloxacin for Children

Clinical Pharmacology and Therapeutics

Volumn 98, Issue 6, 2015, Pages 622-629

  Savic, R M ^a   Ruslami, R ^b   Hibma, J E ^a   Hesseling, A ^c   Ramachandran, G ^d   Ganiem, A R ^b   Swaminathan, S ^d   McIlleron, H ^e   Gupta, A ^f   Thakur, K ^f   Van Crevel, R ^g   Aarnoutse, R ^g   Dooley, K E ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b PADJADJARAN UNIVERSITY   (Indonesia)

^c STELLENBOSCH UNIVERSITY   (South Africa)

^d NATIONAL INSTITUTE FOR RESEARCH IN TUBERCULOSIS   (India)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; ETHAMBUTOL; LEVOFLOXACIN; MOXIFLOXACIN; RIFAMPICIN; TUBERCULOSTATIC AGENT;

ADJUVANT THERAPY; ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID-TO-PLASMA RATIO; CHILDHOOD DISEASE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG EFFICACY; DRUG EXPOSURE; DRUG MEGADOSE; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM PLASMA CONCENTRATION; OPTIMAL DRUG DOSE; PERIPHERAL VOLUME OF DISTRIBUTION; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE; TUBERCULOUS MENINGITIS; VOLUME OF DISTRIBUTION; ADOLESCENT; ADULT; AGE; BIOLOGICAL MODEL; BLOOD; BODY WEIGHT; CHILD; COMPUTER SIMULATION; DOSE CALCULATION; DRUG EFFECTS; INFANT; INTRAVENOUS DRUG ADMINISTRATION; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL (TOPIC); PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); TUBERCULOSIS, MENINGEAL;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGE FACTORS; ANTITUBERCULAR AGENTS; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS, PHASE II AS TOPIC; COMPUTER SIMULATION; DRUG DOSAGE CALCULATIONS; HUMANS; INFANT; LEVOFLOXACIN; MODELS, BIOLOGICAL; MYCOBACTERIUM TUBERCULOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIFAMPIN; TUBERCULOSIS, MENINGEAL;

EID: 84954324342     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.202     Document Type: Article

References (41)

1. Thwaites, G., Chau, T.T., Mai, N.T., Drobniewski, F., McAdam, K. & Farrar, J. Tuberculous meningitis. J. Neurol. Neurosurg. Psychiatry 68, 289-299 (2000).
2. van Well, G.T. et al. Twenty years of pediatric tuberculous meningitis: A retrospective cohort study in the western cape of South Africa. Pediatrics 123, e1-e8 (2009).
3. Karande, S., Gupta, V., Kulkarni, M. & Joshi, A. Prognostic clinical variables in childhood tuberculous meningitis: An experience from Mumbai, India. Neurol. India 53, 191-195; discussion 195-196 (2005).
4. Schoeman, J. et al. Long-term follow up of childhood tuberculous meningitis. Dev. Med. Child Neurol. 44, 522-526 (2002).
5. World Health Organization. Rapid advice: Treatment of tuberculosis in children (WHO Library Cataloguing-in-Publication Data, Geneva, Switzerland, 2010).
6. Ellard, G.A., Humphries, M.J. & Allen, B.W. Cerebrospinal fluid drug concentrations and the treatment of tuberculous meningitis. Am. Rev. Respir. Dis. 148, 650-655 (1993).
7. Savic, R.M. et al. PKPD analysis of rifapentine in patients during intensive phase treatment for tuberculosis from Tuberculosis Trial Consortium studies 29 and 29X. 6th International Workshop on Clinical Pharmacology of Tuberculosis Drugs, Denver, CO, 9 September 2013.
8. Boeree, M.J., Plemper van Balen, G. & Aarnoutse, R.A. High-dose rifampin: How do we proceed? Int. J. Tuberc. Lung Dis. 15, 1133 (2011).
9. Ruslami, R. et al. Intensified regimen containing rifampin and moxifloxacin for tuberculous meningitis: An open-label, randomised controlled phase 2 trial. Lancet Infect. Dis. 13, 27-35 (2013).
10. Pilheu, J.A., Maglio, F., Cetrangolo, R. & Pleus, A.D. Concentrations of ethambutol in the cerebrospinal fluid after oral administration. Tubercle 52, 117-122 (1971).
11. Gundert-Remy, U., Klett, M. & Weber, E. Concentration of ethambutol in cerebrospinal fluid in man as a function of the non-protein-bound drug fraction in serum. Eur. J. Clin. Pharmacol. 6, 133-136 (1973).
12. Radenbach, K.L. Minimum daily efficient dose of ethambutol: General review [in French]. Bull. Int. Union Tuberc. 48, 106-111 (1973).
13. Donald, P.R., Schoeman, J.F., Van Zyl, L.E., De Villiers, J.N., Pretorius, M. & Springer, P. Intensive short course chemotherapy in the management of tuberculous meningitis. Int. J. Tuberc. Lung Dis. 2, 704-711 (1998).
14. Chiang, S.S. et al. Treatment outcomes of childhood tuberculous meningitis: A systematic review and meta-analysis. Lancet Infect. Dis. 14, 947-957 (2014).
15. Thwaites, G.E. et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob. Agents Chemother. 55, 3244-3253 (2011).
16. Koup, J.R., Williams-Warren, J., Weber, A. & Smith, A.L. Pharmacokinetics of rifampin in children. I. Multiple dose intravenous infusion. Ther. Drug Monit. 8, 11-16 (1986).
17. Koup, J.R., Williams-Warren, J., Viswanathan, C.T., Weber, A. & Smith, A.L. Pharmacokinetics of rifampin in children. II. Oral bioavailability. Ther. Drug Monit. 8, 17-22 (1986).
18. Thee, S. et al. Pharmacokinetics of ofloxacin and levofloxacin for prevention and treatment of multidrug-resistant tuberculosis in children. Antimicrob. Agents Chemother. 58, 2948-2951 (2014).
19. Li, F., Nandy, P., Chien, S., Noel, G.J. & Tornoe, C.W. Pharmacometrics-based dose selection of levofloxacin as a treatment for postexposure inhalational anthrax in children. Antimicrob. Agents Chemother. 54, 375-379 (2010).
20. Te Brake, L. et al. Pharmacokinetic/pharmacodynamic analysis of an intensified regimen containing rifampin and moxifloxacin for tuberculous meningitis. Int. J. Antimicrob. Agents 45, 496-503 (2015).
21. World Health Organization. Roadmap for childhood tuberculosis: Toward zero deaths. (2013). http://apps.who.int/iris/bitstream/10665/89506/1/9789241506137-eng.pdf
22. Ramachandran, P., Duraipandian, M., Nagarajan, M., Prabhakar, R., Ramakrishnan, C.V. & Tripathy, S.P. Three chemotherapy studies of tuberculous meningitis in children. Tubercle 67, 17-29 (1986).
23. Schoeman, J. et al. Long-term follow up of childhood tuberculous meningitis. Dev. Med. Child Neurol. 44, 522-526 (2002).
24. Nahata, M.C., Fan-Havard, P., Barson, W.J., Bartkowski, H.M. & Kosnik, E.J. Pharmacokinetics, cerebrospinal fluid concentration, and safety of intravenous rifampin in pediatric patients undergoing shunt placements. Eur. J. Clin. Pharmacol. 38, 515-517 (1990).
25. Boeree, M.J. et al. High-dose rifampin, SQ109 and moxifloxacin for treating TB: The PanACEA MAMS-TB trial. 2015 Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, 25 February 2015. Abstract 95LB.
26. Diacon, A.H. et al. Early bactericidal activity of high-dose rifampin in patients with pulmonary tuberculosis evidenced by positive sputum smears. Antimicrob. Agents Chemother. 51, 2994-2996 (2007).
27. Obermeier, B., Daneman, R. & Ransohoff, R.M. Development, maintenance and disruption of the blood-brain barrier. Nat. Med. 19, 1584-1596 (2013).
28. Heideman, R.L. et al. Phase I trial and pharmacokinetic evaluation of fazarabine in children. Cancer Res. 49, 5213-5216 (1989).
29. Kellie, S.J., Barbaric, D., Koopmans, P., Earl, J., Carr, D.J. & de Graaf, S.S. Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosing: A surrogate marker of brain penetration. Cancer 94, 1815-1820 (2002).
30. Jacobs, R.F., Kearns, G.L., Brown, A.L. & Longee, D.C. Cerebrospinal fluid penetration of imipenem and cilastatin (primaxin) in children with central nervous system infections. Antimicrob. Agents Chemother. 29, 670-674 (1986).
31. Lowe, E.S. et al. Plasma pharmacokinetics and cerebrospinal fluid penetration of thioguanine in children with acute lymphoblastic leukemia: A collaborative Pediatric Oncology Branch, NCI, and Children's Cancer Group study. Cancer Chemother. Pharmacol. 47, 199-205 (2001).
32. Donald, P.R. Cerebrospinal fluid concentrations of antituberculosis agents in adults and children. Tuberculosis (Edinb). 90, 279-292 (2010).
33. Bamrah, S. et al. Treatment for LTBI in contacts of MDR-TB patients, Federated States of Micronesia, 2009-2012. Int. J. Tuberc. Lung Dis. 18, 912-918 (2014).
34. Thee, S. et al. Pharmacokinetics and safety of moxifloxacin in children with multidrug-resistant tuberculosis. Clin. Infect. Dis. 60, 549-556 (2015).
35. Bradley, J.S., Jackson, M.A.; Committee on Infectious Diseases; & American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics 128, e1034-e1045 (2011).
36. Loos, U., Musch, E., Jensen, J.C., Mikus, G., Schwabe, H.K. & Eichelbaum, M. Pharmacokinetics of oral and intravenous rifampin during chronic administration. Klin. Wochenschr. 63, 1205-1211 (1985).
37. Zvada, S.P. et al. Population pharmacokinetics of rifampin, pyrazinamide and isoniazid in children with tuberculosis: In silico evaluation of currently recommended doses. J. Antimicrob. Chemother. 69, 1339-1349 (2014).
38. Sheiner, L.B., Stanski, D.R., Vozeh, S., Miller, R.D. & Ham, J. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine. Clin. Pharmacol. Ther. 25, 358-371 (1979).
39. Jonsson, E.N. & Karlsson, M.O. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58, 51-64 (1999).
40. Lindbom, L., Pihlgren, P. & Jonsson, E.N. PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM. Comput. Methods Programs Biomed. 79, 241-257 (2005).
41. Karlsson, M.O. & Savic, R.M. Diagnosing model diagnostics. Clin. Pharmacol. Ther. 82, 17-20 (2007).